C.CoatsA
There is evidence linking an increase of the nephrotoxin indoxyl sulfate in the serum of uremic patientswhich is caused by poor renal secretionto gut microbiota dysbiosis toward a greater abundance of aerobic indole-producing bacteria (such as Escherichia coli ) (117, 118)

Jenn and I discuss: How natural GLP-1 production can decline with age Why under-fueling is still the primary issue for many athletes Different types and forms of GLP-1 meds Who should (and shouldn't) consider these medications Potential risks of GLP-1 use, including muscle loss, bone density loss, and GI distress Potential benefits to inflammation, autoimmune conditions, gut health, and mood Nutrition and supplement strategies when appetite is lower Dosing and microdosing for therapeutic use, not just weight loss Why some athletes cycle on and off these meds, or may only need them for a short period of time Why Jenn takes most clients off GLP-1s during race training The stigma around GLP-1 use among athletes Jenn's own story: early menopause, a cardiovascular family history, and how a short course changed her running Why solid diet and lifestyle habits must always come first I hope this episode helps you better understand the complexities of GLP-1 medications in endurance athletes, and why there's rarely a simple yes-or-no answer to the questions we explore together

The operations mainly involve phony or illegal versions of Novo Nordisk's diabetes drug Ozempic and its obesity drug Wegovy as well as Eli Lilly's Mounjaro and Zepbound
Clients often describe medical weight loss as a turning point in their wellness journey